Phosphorus Control

• Renvela^® (sevelamer carbonate) maintains serum phosphorus at a mean level of 4.6 mg/dL in dialysis patients.¹

• Renvela is an effective first-line monotherapy for controlling serum phosphorus with an average prescribed dose of three 800 mg tablets per meal.^1,2
• During a crossover study, Renvela was shown to be equivalent to Renagel^® (sevelamer hydrochloride) in reducing serum phosphorus in dialysis patients.^1,3
• Renvela is indicated for use in both hemodialysis and peritoneal dialysis patients.³

^*Kidney Disease Outcomes Quality Initiative

References

1. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, cross-over design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007;68(6):386-391.

2. Data on file, Genzyme Corp.

3. Renvela Package Insert, Cambridge, MA: Genzyme Corp; 2007.

4. National Kidney foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1-S201

Important Treatment Considerations

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer. Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets. For more information, please see Full Prescribing Information for Renvela, Full Prescribing Information for Renagel or call Genzyme Medical Information at 1-800-847-0069.